Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

LXRX

Live52w high -16.4%

Annual Quarterly

Core line items from LXRX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Entity: Lexicon Pharmaceuticals, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-04	Q1 2025 2025-03-31	Annual 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30
Revenue	$3.90M	$1.26M	$6.00M	$4.45M	$2.71M
Operating Income	Not available	$-25.68M	$-197.12M	$-164.38M	$-100.69M
Net Income	Not available	$-25.30M	$-200.40M	$-166.64M	$-53.43M
EPS (Diluted)	$-0.06	$-0.07	$-0.63	$-0.54	$-0.37
Total Assets	Not available	$297.67M	$298.42M	$321.12M	$373.36M
Total Liabilities	Not available	$174.64M	$152.47M	$142.61M	$133.38M
Cash & Equivalents	Not available	$62.89M	$66.66M	$34.55M	$35.62M
Free Cash Flow OCF − CapEx	Not available	Not available	$-179.81M	$-157.85M	$-103.92M
Shares Outstanding	Not available	362.07M	363.02M	306.11M	278.11M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from LXRX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -16.4%

Entity: Lexicon Pharmaceuticals, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-04	Q1 2025 2025-03-31	Annual 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30
Revenue	$3.90M	$1.26M	$6.00M	$4.45M	$2.71M
Operating Income	Not available	$-25.68M	$-197.12M	$-164.38M	$-100.69M
Net Income	Not available	$-25.30M	$-200.40M	$-166.64M	$-53.43M
EPS (Diluted)	$-0.06	$-0.07	$-0.63	$-0.54	$-0.37
Total Assets	Not available	$297.67M	$298.42M	$321.12M	$373.36M
Total Liabilities	Not available	$174.64M	$152.47M	$142.61M	$133.38M
Cash & Equivalents	Not available	$62.89M	$66.66M	$34.55M	$35.62M
Free Cash Flow OCF − CapEx	Not available	Not available	$-179.81M	$-157.85M	$-103.92M
Shares Outstanding	Not available	362.07M	363.02M	306.11M	278.11M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.